Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Bortezomib (Velcade®)
DRUG
2 trials
Sponsors
The Rogosin Institute
, Intergroupe Francophone du Myelome
Conditions
Chronic Kidney Disease
IgA Nephropathy
Multiple Myeloma, Newly Diagnosed
Phase 3
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Recruiting
NCT06918002
Intergroupe Francophone du Myelome
Multiple Myeloma, Newly Diagnosed
Start: 2025-07-09
End: 2036-05-01
Target: 824
Updated: 2026-04-02
Phase 4
Pilot Study of Velcade® in IgA Nephropathy
Completed
NCT01103778
The Rogosin Institute
Chronic Kidney Disease, IgA Nephropathy
Start: 2010-07-31
End: 2017-04-17
Updated: 2018-11-16
Related Papers
Bortezomib for Reduction of Proteinuria in IgA Nephropathy.
2018-03-11
48 citations